NCT07740239Recruiting
A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2050 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 13 Nov 2024
- Primary completion date
- 30 Dec 2030
- Lead sponsor
- Tampere University Hospital
- Diseases
- Prostate cancer, Lung cancer, Childhood cancers
- NCT number
- NCT07740239
What you commit to
- Study type: Observational
- Planned participants: 2050
- From 13 Nov 2024 to the primary completion date, 30 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not willing or unable to give written consent
- Patient not deemed suitable for the study by the researcher approaching the patient
Who the study is looking for
- Suspected or diagnosed disease
- ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
- Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
- Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
- Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
- Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tampere University Hospital Coordinator of this site? Confirm its status | Tampere | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.